421 COMPARATIVE BIOAVAILABILITY OF 1% TOPICAL DICLOFENAC SODIUM GEL AND ORAL DICLOFENAC SODIUM IN HEALTHY VOLUNTEERS: A STEADY-STATE, RANDOMIZED, CROSSOVER SYSTEMIC STUDY  by Kienzler, J.-L. et al.
Osteoarthritis and Cartilage Vol. 15, Supplement C C229
Table 1
Adjusted* ORs (95% CI)
VK treatment VK levels >1nM vs ≤1nM
vs PBO at ﬁnal study visit
All Trial Subjects: (N=378)
ROA 1.03 (0.80-1.34) 0.96 (0.73-1.25)
P=0.8 P=0.7
OST 1.04 (0.68-1.57) 1.17 (0.74-1.85)
P=0.9 P=0.5
JSN 0.95 (0.64-1.40) 0.73 (0.49-1.10)
P=0.8 P=0.1
Subjects with VK ≤1nM at baseline: (N=221)
ROA 0.86 (0.62-1.19) 0.78 (0.56-1.07)
P=0.3 P=0.1
OST 0.87 (0.55-1.39) 0.88 (0.56-1.40)
P=0.6 P=0.5
JSN 0.83 (0.50-1.37) 0.53 (0.32-0.89)
P=0.5 P=0.02
*adjusted for age, sex, BMI, smoking status, baseline 25(OH)-vitamin D level,
educational level, adherence to supplements, and baseline physical activity as
measured by the PASE.
baseline, the group to whom therapy should be targeted, may
have had a beneﬁt, but there was inadequate power to address
this question deﬁnitively. This trial may not have been of long
enough duration or of sufﬁcient size to detect a true effect.
Treatment of VK deﬁciency which is common in elders may have
an as yet unproven favorable effect on disease.
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Purpose: To compare the systemic bioavailability of a new gel
formulation of diclofenac sodium 1% (DSG) when applied either
to 1 knee (normal use) or to 2 knees and 2 hands (maximal
exposure) to oral dosing with 50-mg diclofenac sodium enteric-
coated tablets in healthy age-matched volunteers representative
of the osteoarthritis (OA) population. The local tolerability of the
topical treatments was also assessed.
Methods: 40 Caucasians, 20 men and 20 women, of mean
age 59.9 years (range, 50 to 74) and mean BMI 26 kg/m2
(range, 20-33 kg/m2) were included in a single-center, open-
label, randomized, 3-way crossover study. Subjects received the
following three 7-day treatments in random order, separated by
14-day washout periods: A) 10 mg/cm2 i.e., 4 g gel applied qid
to 1 knee (total 16 g gel/day on surface area ∼400 cm2); B)
4 g gel qid per knee to both knees and 2 g gel qid per hand
applied to both hands (total 48 g gel/day on surface area ∼1200
cm2); and C) 50-mg tablets orally tid. Scheduled blood samples
were taken from Day 1 to Day 7 in each period. Cumulative urine
was collected over 24 h on Day 1 for Treatments A and B only
and over 24 h on Day 7 for all treatments. Pharmacokinetic (PK)
analysis included: concentration proﬁle of diclofenac in plasma
and derived AUC0-24 on Day 1 of treatment B; concentration
proﬁle of diclofenac in plasma at steady state and derived PK
parameters (Cmax, AUC0-24) on Day 7 for each treatment; amount
excreted into urine over 0 to 24 h (Ae0-24) for diclofenac and 4’-
OH-diclofenac (primary urinary metabolite) on Day 1 (treatments
A and B only) and on Day 7 for each treatment.
Results: 39 out of 40 subjects were included in the PK analysis.
Steady-state was reached by Day 7 for Treatments B and C, but
not for Treatment A. Diclofenac concentration peaked after each
administration of the oral treatment, but no obvious peak was
observed with the gel applications, and plasma concentration
over time was ﬂat (illustrated below in Figure 1).
Figure 1
The mean Cmax and AUC0-24 for treatment B (Cmax: 53.8 ± 32.0
ng/mL; AUC0-24: 807 ± 478 ngh/mL) were more than 3 times
those of treatment A (Cmax: 15.0 ± 7.33 ng/mL; AUC0-24: 233 ±
128 ngh/mL); these were both 1 or 2 orders of magnitude lower
than for treatment C (Cmax: 2270 ± 778 ng/mL; AUC0-24: 3890
± 1710 ngh/mL). Mean urinary excretion of diclofenac and its
major metabolite, 4’-OH-diclofenac, over 24 h was 3 to 4 times
higher for Treatment B than for Treatment A on Day 1 and 2 to
3 times higher on Day 7. Ratios of treatments on Day 7 and of
Day 7 to Day 1 for treatments A and B for the main bioavailability
parameters are provided below:
Ratios (N=39) Cmax AUC0-24 Ae0-24 diclo Ae0-24 4′-OH a
(%) (%) (%) (%)
Day 7
B/A 349 340 273 250
(302-403) (294-394) (224-332) (207-302)
A/C 0.633 5.79 2.51 2.21
(0.548-0.733) (5.00-6.70) (2.06-3.06) (1.82-2.68)b
A/C 0.633 5.79 2.51 2.21
B/C 2.21 19.7 6.85 5.52
(1.91-2.56) (17.0-22.8) (5.63-8.34) (4.56-6.69)b
Day 7/Day 1
A - - 493 666
(417-581) (561-790)
B - 417 285 402
(367-474) (248-327) (350-462)
a Primary urinary metabolite of diclofenac; b N=38.
Ten percent of subjects experienced mild local tolerability ad-
verse events (AEs) after topical Treatments A and B, while 8%
experienced mild gastrointestinal AEs after oral Treatment C.
General tolerability appeared better with topical Treatments A
and B (local reactions only) than with oral Treatment C.
Conclusions:Compared with oral diclofenac, systemic exposure
to diclofenac with topical DSG 1% ranged from 6% (17-fold lower)
for 1 knee to 20% for both hands and knees. DSG 1% was well
tolerated by the study population.
